Abstract 297P
Background
Radiotherapy and chemotherapy, or a combination of both have a significant role in the management of cervical cancer. In order to reduce the burden of cervical cancer in a tangible way especially in Indonesia, the need for both modalities demand must be assessed. Considering this, it is necessary to discuss and determine the calculation of the optimal and actual Radiotherapy and Chemotherapy Utilization Rate (RUR and CUR), also the unmet need (gap) between the two rates for cervical cancer in Indonesia.
Methods
Descriptive study of cross-sectional design, total sampling method by taking secondary data from cancer registries and/or internal medical records of participating hospitals with radiotherapy centres in Indonesia in 2019. Data were then separated into hospital data (all cervical cancer cases in the hospital) and RT data (cases from radiotherapy department only).
Results
The total data from the 33 participating hospitals was 4937, divided into 3617 hospital data and 1320 RT data.
The average age of patients was 48-52 years (7-91 years). Patient domicile was mostly from Java Island. Stage III was the most common stage (39.4%). Cervical cancer management was dominated by radiotherapy alone and chemoradiation (28.5% and 27.4%).
Optimal rates can only be based on hospital data that have complete stage attributes.
The optimal, actual RUR and unmet need values were 97.2% (90.9-97.4%), 61.24%, and 36.7% (32.62-37.13%), respectively.
For CUR, the optimal, actual and unmet need values were 87.8% (81-88%), 40%, 54.5% (50.8-55%), respectively.
The actual RUR and CUR for combined data were 70.93% and 39.6%, respectively.
Conclusions
The optimal and actual values of RUR and CUR for cervical cancer in Indonesia still have a large gap, indicating more need for demand of both modalities.
Efforts are needed to increase the actualization of RUR and CUR closer to their optimal rate. Factors affecting RUR and CUR should be explored universally including the patient, clinician, and healthcare system aspects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract